Αποτελέσματα Αναζήτησης
25 Ιαν 2023 · In this study, effectiveness against hospitalization or death was 24.9% after a monovalent booster and 61.8% after a bivalent booster. Protection has waned over time.
11 Μαΐ 2023 · In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL).
13 Απρ 2023 · Our findings suggest that, in adults aged 65 years or older, the vaccine effectiveness of the bivalent mRNA vaccine booester dose is 72% (95% CI 60–81) for COVID-19 related hospitalisation and 68% (42–82) for COVID-19-related death. Implications of all the available evidence.
16 Σεπ 2022 · Results. Interim results are presented. Sequential groups of participants received 50 μg of mRNA-1273.214 (437 participants) or mRNA-1273 (377 participants) as a second booster dose. The...
12 Απρ 2023 · In a trial of two bivalent Covid-19 boosters, effectiveness against severe infection resulting in hospitalization or death reached a level of 67.4% after 2 weeks and decreased to 38.4% after...
29 Δεκ 2022 · The objectives phase 2/3 clinical trial aimed to assess the safety, reactogenicity, and immunogenicity of bivalent vaccine mRNA-1273.214 with monovalent mRNA-1273 28 days after their second booster dose.
10 Αυγ 2023 · Two hundred two eligible participants were stratified by history of confirmed SARS-CoV-2 infection and randomized 1:1 to receive 1 or 2 doses (separated by 56 days) of Moderna mRNA Beta/Omicron BA.1 bivalent vaccine (50 μg).
